



Trading Floor Research

Welcome to the ——Trading Floor——



02/07/21

- This Trading Floor Research report contains:
- This week's powerful buy signal in the Medical-Biotech industry group.
- Orgenics Inc. (OGEN). A COVID-19 protective immunity buy candidate in the Medical-Biotech industry group.

TFR

Trading Floor Research

Welcome to the
—Trading Floor –



Biotech Buy Signal

Institutional cash was pouring into Biotech's this week. The Medical-Biotech industry group chart on the next slide verifies this. It shows six up days in a row with above average increasing volume. A very rare and powerful sextuple accumulation day pattern. Digging into where the action was happening I found two themes this past week. I have found the market to be very thematic lately. The Biotech's were no exception.

One theme carrying stocks in the group were Alzheimer drug companies. These included names like Anavex Life Sciences (AVXL) and Annovis Bio Inc. (ANVS). I've included both charts with Fib target numbers. Both stocks traded in a similar pattern, and both closed under key Fib numbers. We must wait to see if they both land on the next lower target number. This could lead to a powerful follow-on trade. I will keep you posted.

The next theme coming back in style is COVID-19 related names. Stocks like Enlivex Therapeutics (ENLV) an Israeli developer of a treatment for variant strains of COVID-19 broke out. I will watch for a retracement to advise when to buy. Our test-kit company for variant strains T2 Biosystems Inc. (TTOO) made a good move and is up 55% this past week.

A COVID-19 buy candidate in today's TFR report is Oragenics Inc. (OGEN). Many more will follow as variant strains keep showing up in the US and other countries.







TFR

Trading Floor Research

Welcome to the
Trading Floor—



- Buy candidate: Oragenics Inc. (OGEN)
- Industry Group: Medical-Biotech industry group
- OGEN will move with the COVID-19 stocks
- OGEN stabilized pre-fusion spike protein CoV-2 S-2P demonstrates protective immunity for COVID-19.
- OGEN is in the handle of a cup-with-handle base that started in July 2020. A short-term resistance point will be at 1.23. This is 50% of range of the base.
- Buy when stock crosses **1.09** with volume. This is where the downward sloping trendline and the Fib target number cross
- Start position at 3-star(***)
- Under massive accumulation with an Up/Down Volume ratio of 4.2.
- OGEN closed at **1.05** on Friday. **After hours it traded at 1.06**.
- Buy if/when OGEN breaks 1.09.
- 1st target price: 2.25
 - 2nd Target price between **3.15 and 3.41**.
 - IPO VWAP at .99.

Stop sell price: Close below .99.







Trading Floor Research

Welcome to the
—Trading Floor—

Understanding the Stock Market.

4th Class tomorrow Monday February 8,2021 at the USW Burns Harbor Career Development Center.

In this class you will learn how to identify leadership industry groups, and leadership stocks within those groups.

A morning and afternoon class will be given:

- 8:30 am-10:30 am
- 4:00 pm-6:00 pm

Get on the right track with your investments for the new year

Invite a family member or friend





TFR open positions as of 02/07/2021:

NBAC	12/08/20	(3-star)	+23.69%
THCA	12/13/20	(1-star)	+3.43%
ARYA	01/12/21	(2-star)	-1.66%
TTOO	01/24/21	(2-star)	+64.45%
XELA	01/24/21	(2-star)	+23.45%
MBII	02/02/21	(2-star)	+27.72%
USWS	02/04/21	(3-star)	+7.36%





Results of TFR closed positions as of 02/07/2021:

XPEV Sold position +41.83%

DADA Stopped out -12.6%

GPRO Stopped out -2.31%

FUV Sold position +67.34%

BLNK Sold position +76.25%

OPTT Sold ½ position +128%

OPTT Stopped out 1/2 position +49.13%

BBIO Sold Position +21.81%

CVAC Sold Position +66.81%

NGMS Stopped out -11.22%

EH Sold Position +61.78%

UFAB Sold Position +43.60%





Results of TFR closed positions as of 02/07/2021:

OTIC	Sold position 12/22/20	+41.80%
BTBT	Sold position 12/30/20	+101.15%
LUNG	Sold position 12/31/20	+41.88%
GBTC	Sold position 01/05/21	+95.29%
ZKIN	Sold ½ position 01/05/21	+28.57%
TGC	Sold position 01/28/21	+309.82%
SNMP	Sold position 01/28/21	+122.58%
GP	Sold position 01/25/21	+41.29%
GMDA	Sold position 01/26/21	-6.87%
TUSK	Sold position 01/27/21	+1.77%
ZKIN	Sold position 01/27/21	+16.17%




Results of TFR closed positions as of 02/07/2021:

CLIR	Sold position 01/28/21	+17.44%
VVPR	Sold position 01/27/21	+34.13%
CHNR	Sold position 01/27/21	-18.01%








¹The results are not (or may not be) representative of the performance of all selections made by Trading Floor Research (TFR) newsletter.


We look for investment resources and inform you of these resources, which you may choose to use in making your own investment decisions. TFR is providing information on this resource to you subject to the TFR "Terms and Conditions of Service" disclaimer.


Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice.





Disclaimer: The information, opinions and ideas expressed herein are for informational and educational purposes only and are based on research conducted and presented solely by the author. The information presented does not represent the views of the author only and does not constitute a complete description of any investment service. In addition, nothing presented herein should be construed as investment advice, as an advertisement or offering of investment advisory services, or as an offer to sell or a solicitation to buy any security. The data presented herein were obtained from various third-party sources. While the data is believed to be reliable, no representation is made as to, and no responsibility, warranty or liability is accepted for the accuracy or completeness of such information. International investments are subject to additional risks such as currency fluctuations, political instability and the potential for illiquid markets. Past performance is no guarantee of future results. There is risk of loss in all trading. Back tested performance does not represent actual performance and should not be interpreted as an indication of such performance. Also, back tested performance results have certain inherent limitations and differs from actual performance because it is achieved with the benefit of hindsight.





Disclaimer

Before using this site, please make sure that you note the following important information:

Do your Own Research

Our content is intended to be used and must be used for informational purposes only. It is very important to do your own analysis before making any investment based on your own personal circumstances. You should take independent financial advice from a professional in connection with, or independently research and verify, any information that you find on our Website and wish to rely upon, whether for the purpose of making an investment decision or otherwise.

The content of this email is confidential and intended for the recipient specified in message only. It is strictly forbidden to share any part of this message with any third party, without a written consent of the sender. If you received this message by mistake, please reply to this message and follow with its deletion, so that we can ensure such a mistake does not occur in the future.